|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.08 USD | -1.51% |
|
-4.45% | +50.00% |
| Mar. 10 | Novavax, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-10-2026 03:40 PM | |
| Mar. 03 | Novavax, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 02:30 PM |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -50.69 | -16.67 | -17.02 | -8.63 | 25.72 | |||||
Return on Total Capital | -164.51 | -519.71 | 152.16 | 36.39 | -335.14 | |||||
Return On Equity % | -1.27K | 133.49 | 80.69 | 27.97 | -117.16 | |||||
Return on Common Equity | -1.27K | 133.49 | 80.69 | 27.97 | -117.16 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | -121.11 | -7.87 | -9.63 | 16.49 | 63.52 | |||||
SG&A Margin | 26.03 | 24.66 | 46.5 | 47.44 | 13.39 | |||||
EBITDA Margin % | -146.03 | -31.07 | -51.94 | -26.89 | 52.59 | |||||
EBITA Margin % | -147.1 | -32.53 | -56.14 | -34 | 50.13 | |||||
EBIT Margin % | -147.13 | -32.53 | -56.14 | -34 | 50.13 | |||||
Income From Continuing Operations Margin % | -152.12 | -33.2 | -55.41 | -27.49 | 39.19 | |||||
Net Income Margin % | -152.12 | -33.2 | -55.41 | -27.49 | 39.19 | |||||
Net Avail. For Common Margin % | -152.12 | -33.2 | -55.41 | -27.49 | 39.19 | |||||
Normalized Net Income Margin | -93.48 | -20.61 | -33.59 | -19.38 | 32.34 | |||||
Levered Free Cash Flow Margin | 63.46 | -10.76 | -99.54 | -25.75 | -29.55 | |||||
Unlevered Free Cash Flow Margin | 64.61 | -10.14 | -98.63 | -23.91 | -28.29 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.55 | 0.82 | 0.49 | 0.41 | 0.82 | |||||
Fixed Assets Turnover | 5.02 | 5.95 | 2.21 | 1.72 | 6.11 | |||||
Receivables Turnover (Average Receivables) | 3.2 | 7.38 | 5.18 | 3.36 | 10.46 | |||||
Inventory Turnover (Average Inventory) | - | 93.86 | 27.52 | 22.58 | 40.39 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 0.9 | 0.69 | 0.7 | 0.98 | 2.13 | |||||
Quick Ratio | 0.82 | 0.58 | 0.53 | 0.89 | 1.83 | |||||
Operating Cash Flow to Current Liabilities | 0.14 | -0.17 | -0.44 | -0.08 | -0.53 | |||||
Days Sales Outstanding (Average Receivables) | 114.15 | 49.48 | 70.43 | 108.79 | 34.88 | |||||
Days Outstanding Inventory (Average Inventory) | - | 3.89 | 13.26 | 16.21 | 9.04 | |||||
Average Days Payable Outstanding | 13.06 | 28.95 | 58.81 | 59.39 | 29.26 | |||||
Cash Conversion Cycle (Average Days) | - | 24.42 | 24.88 | 65.6 | 14.66 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | -149.03 | -97.26 | -39.14 | -42.23 | -217.64 | |||||
Total Debt / Total Capital | 303.97 | -3.56K | -64.32 | -73.11 | 185 | |||||
LT Debt/Equity | -103.1 | -39.08 | -35.22 | -39.49 | -207.95 | |||||
Long-Term Debt / Total Capital | 210.29 | -1.43K | -57.88 | -68.37 | 176.76 | |||||
Total Liabilities / Total Assets | 113.65 | 128.07 | 139.88 | 139.98 | 110.86 | |||||
EBIT / Interest Expense | -79.83 | -32.43 | -38.31 | -11.55 | 24.98 | |||||
EBITDA / Interest Expense | -49.81 | -25.51 | -27.92 | -9.14 | 26.58 | |||||
(EBITDA - Capex) / Interest Expense | -52.53 | -29.99 | -31.65 | -9.79 | 26.34 | |||||
Total Debt / EBITDA | -0.5 | -1.22 | -0.7 | -1.44 | 0.46 | |||||
Net Debt / EBITDA | 0.94 | 1.42 | 0.72 | 3.6 | -0.76 | |||||
Total Debt / (EBITDA - Capex) | -0.47 | -1.03 | -0.62 | -1.34 | 0.47 | |||||
Net Debt / (EBITDA - Capex) | 0.89 | 1.21 | 0.63 | 3.36 | -0.77 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 141.02 | 72.89 | -50.36 | -30.65 | 64.69 | |||||
Gross Profit, 1 Yr. Growth % | 411.45 | -88.76 | -39.27 | -310.11 | 678.6 | |||||
EBITDA, 1 Yr. Growth % | 309.14 | -63.22 | -17 | -64.1 | -422.1 | |||||
EBITA, 1 Yr. Growth % | 307.86 | -61.77 | -14.35 | -58 | -342.85 | |||||
EBIT, 1 Yr. Growth % | 307.37 | -61.77 | -14.35 | -58 | -342.85 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 316.91 | -62.27 | -17.16 | -65.6 | -334.83 | |||||
Net Income, 1 Yr. Growth % | 316.91 | -62.27 | -17.16 | -65.6 | -334.83 | |||||
Normalized Net Income, 1 Yr. Growth % | 312.59 | -61.88 | -19.11 | -59.99 | -374.78 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 222.51 | -64.09 | -35.72 | -77.22 | -309.01 | |||||
Accounts Receivable, 1 Yr. Growth % | 73.65 | -81.9 | 260.84 | -63.57 | -1.7 | |||||
Inventory, 1 Yr. Growth % | - | 313.47 | 13.67 | -79.02 | 31.96 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 43.18 | 50.64 | 22.6 | -38.9 | -77.43 | |||||
Total Assets, 1 Yr. Growth % | 62.83 | -12.34 | -20.42 | -13.19 | -24.6 | |||||
Tangible Book Value, 1 Yr. Growth % | -200.37 | 57.38 | 11.04 | -13.39 | -67.02 | |||||
Common Equity, 1 Yr. Growth % | -156.07 | 80.3 | 13.07 | -12.98 | -79.52 | |||||
Cash From Operations, 1 Yr. Growth % | -859.14 | -228.79 | 71.65 | -87.78 | 180.34 | |||||
Capital Expenditures, 1 Yr. Growth % | 5.24 | 63.4 | -39.62 | -75.72 | -57.42 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -376.41 | -129.33 | 359.03 | -82.06 | 88.99 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -391.93 | -127.13 | 382.94 | -83.19 | 94.89 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 683.73 | 104.14 | -7.36 | -41.33 | 6.87 | |||||
Gross Profit, 2 Yr. CAGR % | 281.91 | -24.18 | -73.87 | 12.14 | 174.42 | |||||
EBITDA, 2 Yr. CAGR % | 267.53 | 22.67 | -44.75 | -45.42 | 7.53 | |||||
EBITA, 2 Yr. CAGR % | 261.68 | 24.79 | -42.78 | -40.02 | 0.99 | |||||
EBIT, 2 Yr. CAGR % | 260.75 | 24.79 | -42.78 | -40.02 | 0.99 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 262.51 | 25.42 | -44.09 | -46.62 | -10.12 | |||||
Net Income, 2 Yr. CAGR % | 262.51 | 25.42 | -44.09 | -46.62 | -10.12 | |||||
Normalized Net Income, 2 Yr. CAGR % | 247.83 | 25.42 | -44.47 | -43.11 | 4.86 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 106.32 | 7.61 | -51.96 | -61.74 | -31.01 | |||||
Accounts Receivable, 2 Yr. CAGR % | 678.88 | -43.93 | -19.17 | 14.65 | -40.16 | |||||
Inventory, 2 Yr. CAGR % | - | - | 116.79 | -51.16 | -47.38 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 384.64 | 46.05 | 35.9 | -13.45 | -62.87 | |||||
Total Assets, 2 Yr. CAGR % | 285.98 | 19.47 | -16.48 | -16.88 | -19.1 | |||||
Tangible Book Value, 2 Yr. CAGR % | 41.77 | 25.07 | 32.2 | -1.93 | -46.55 | |||||
Common Equity, 2 Yr. CAGR % | 37.5 | 0.55 | 42.78 | -0.81 | -57.79 | |||||
Cash From Operations, 2 Yr. CAGR % | 53.75 | 212.69 | 48.69 | -54.2 | -41.46 | |||||
Capital Expenditures, 2 Yr. CAGR % | 456.38 | 27.86 | -0.67 | -61.71 | -67.84 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 199.81 | -9.97 | 16.02 | -9.26 | -41.78 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 219.79 | -11.01 | 14.46 | -9.9 | -42.76 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 222.14 | 373.56 | 27.41 | -15.89 | -17.24 | |||||
Gross Profit, 3 Yr. CAGR % | 115.09 | 17.91 | -29.59 | -56.72 | 99.79 | |||||
EBITDA, 3 Yr. CAGR % | 116.15 | 70.64 | 7.69 | -52.15 | -1.36 | |||||
EBITA, 3 Yr. CAGR % | 113.52 | 71.02 | 10.08 | -48.38 | -4.4 | |||||
EBIT, 3 Yr. CAGR % | 113.25 | 70.71 | 10.08 | -48.38 | -4.4 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 111.33 | 70.52 | 9.23 | -52.45 | -12.53 | |||||
Net Income, 3 Yr. CAGR % | 111.33 | 70.52 | 9.23 | -52.45 | -12.53 | |||||
Normalized Net Income, 3 Yr. CAGR % | 110.15 | 66.46 | 8.36 | -50.22 | -3.83 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 32.86 | 15.19 | -9.37 | -62.54 | -32.61 | |||||
Accounts Receivable, 3 Yr. CAGR % | - | 122.29 | 4.29 | -38.03 | 8.92 | |||||
Inventory, 3 Yr. CAGR % | - | - | - | -0.46 | -31.98 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 111.47 | 227.08 | 37.77 | 4.11 | -44.71 | |||||
Total Assets, 3 Yr. CAGR % | 131.39 | 135.49 | 4.34 | -15.4 | -19.54 | |||||
Tangible Book Value, 3 Yr. CAGR % | 29.16 | 46.32 | 20.21 | 14.82 | -31.8 | |||||
Common Equity, 3 Yr. CAGR % | 27.94 | 50.5 | 4.56 | 21.05 | -41.38 | |||||
Cash From Operations, 3 Yr. CAGR % | 20.45 | 44.93 | 156.03 | -35.35 | -16.22 | |||||
Capital Expenditures, 3 Yr. CAGR % | 247.32 | 263.32 | -0.43 | -37.89 | -60.33 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 93.79 | 38.14 | 54.96 | -37.73 | 15.88 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 99.79 | 40.51 | 56.38 | -39.61 | 16.52 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 136.93 | 129.43 | 95.68 | 105.39 | 18.76 | |||||
Gross Profit, 5 Yr. CAGR % | 44.21 | 2.6 | -7.44 | 3.4 | 21.33 | |||||
EBITDA, 5 Yr. CAGR % | 45.06 | 30.62 | 25.25 | 8.16 | 7.63 | |||||
EBITA, 5 Yr. CAGR % | 44.43 | 30.63 | 26.1 | 12.47 | 6.35 | |||||
EBIT, 5 Yr. CAGR % | 44.35 | 30.29 | 25.99 | 12.34 | 6.35 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 44.17 | 29.06 | 24.16 | 7.16 | 1.03 | |||||
Net Income, 5 Yr. CAGR % | 44.17 | 29.06 | 24.16 | 7.16 | 1.03 | |||||
Normalized Net Income, 5 Yr. CAGR % | 43.68 | 28.89 | 23.4 | 8.34 | 6.94 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 2.54 | -7.69 | -11.55 | -25.88 | -18.74 | |||||
Accounts Receivable, 5 Yr. CAGR % | - | - | - | 70.57 | -16.49 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 46.25 | 61.92 | 76.8 | 92.18 | -18.45 | |||||
Total Assets, 5 Yr. CAGR % | 45.56 | 49.5 | 53.93 | 55.26 | -5.76 | |||||
Tangible Book Value, 5 Yr. CAGR % | 49 | 36.04 | 30.11 | 24.68 | -13.08 | |||||
Common Equity, 5 Yr. CAGR % | 129.31 | 44.19 | 33.68 | 27.38 | -27.26 | |||||
Cash From Operations, 5 Yr. CAGR % | 4.53 | 23.55 | 31.03 | -8.58 | 41.89 | |||||
Capital Expenditures, 5 Yr. CAGR % | 25.86 | 84.29 | 108.28 | 47.71 | -36.65 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 33.59 | 23.04 | 57.84 | 16.76 | 4.75 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 35.16 | 24.09 | 59.88 | 17.63 | 4.61 |
- Stock Market
- Equities
- NVAX Stock
- Financials Novavax, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















